Plain-English translation of NCT05799118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →This study is gathering genetic information from up to 30,000 people worldwide who have been diagnosed with sickle cell disease, thalassemia, or related blood disorders. By analyzing the DNA of many patients from different backgrounds, researchers hope to discover which genetic factors influence how severe the disease becomes and what complications people experience. This knowledge could help doctors predict health risks earlier and personalize treatment plans.
Sickle cell disease and thalassemia vary dramatically from person to person — some people have mild symptoms while others face serious complications like stroke, chronic pain, or organ damage. Doctors currently don't have reliable ways to predict who will develop these severe problems. This study aims to identify the hidden genetic factors that determine disease severity so treatment can be tailored to individual patients and risks can be identified early.
You likely qualify if…
You likely don't qualify if…
If you join, you would likely have a one-time visit where researchers will collect a small blood sample and gather information about your health history and how your disease has affected you. The study may also involve reviewing your existing medical records to understand your symptoms and disease severity. There is no ongoing medication to take or multiple visits required — this is primarily a data and sample collection study that helps build a research resource for future discoveries.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Angola
Argentina
Belgium
Brunei